RNA logo

Atrium Therapeutics, Inc.

RNA
Healthcare|Biotechnology|US
$8.34
+0.02 (+0.24%)
Tangible Book / Share
$12.54
Cash / Share
$15.45
Next Earnings Report
Nov 12, 2026
EPS est. -$0.81 · Revenue est. $15.0M
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.

Upcoming Data Readouts (34)

Dec 2026
Est. completion
NAUrge Incontinence
Percutaneous Nerve Evaluation Trial Time
NCT06226220n=193
Jan 2027
Est. completion
Childhood Cancers
Assessing and Addressing Health-Related Social Needs Among Families of Children With Cancer
NCT07278414n=60
Jan 2027
Est. completion
NACancer
Resilience Enhancement Using Electronic Frailty Index-Directed Care Pathway
NCT07175376n=32
Jan 2027
Est. completion
Non-small Cell Lung Cancer
Cancer-related Fatigue During Maintenance Immunotherapy for Non-small Cell Lung Cancer (NSCLC): a Qualitative Study
NCT06567704n=20
Apr 2027
Est. completion
Clonal Hematopoiesis of Indeterminate Potential
Pre-malignant States to Hematologic Malignancies in Firefighters
NCT06870760n=300
Jun 2027
Est. completion
Cancer
Comprehensive Care for AYA: Needs Assessment Survey
NCT07196241n=300
Jun 2027
Est. completion
Pancreatic Cancer
WATD and Cancer-Related Fatigue: A Study For Patients Undergoing Anti-Cancer Treatment
NCT06291324n=46
Jul 2027
Est. completion
Myeloproliferative Neoplasm
Evaluation of the Pathobiology of CALR-mutated MPN Cells
NCT06480591n=35
Jul 2027
Est. completion
NABreast Cancer
Utility of a Mobile Application for Young Women With Breast Cancer
NCT07009093n=120
Jul 2027
Est. completion
Leukemia, Myeloid, Acute
Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML
NCT06580106n=50
Jul 2027
Est. completion
Genitourinary Cancer
Discharge Medication Use Post-Operatively in GU Cancer Patients
NCT06795087n=684
Oct 2027
Est. completion
P3Renal Carcinoma
R.E.C.K vs Exparel in Robotic Nephrectomy
NCT07092566n=170
Nov 2027
Est. completion
NAPediatric Cancer
LCI-PED-NOS-EXER-001: Exercise in Pediatric Oncology Patients
NCT05058508n=60
Dec 2027
Est. completion
Peripheral Arterial Disease
Advanta VXT and Flixene PMCF Registry
NCT07161583n=1,000
Feb 2028
Est. completion
NAHematologic Malignancy
ONC-MM-2407: The Effect of Virtual Reality Headsets on Pain and Anxiety in the Peri and Post Bone Marrow Biopsy Period
NCT07203534n=160
May 2028
Est. completion
NAAcute Myeloid Leukemia
ONC-LEUK-2406: The Impact of Systematic Financial Navigation in Acute Myeloid Leukemia
NCT06945042n=120
May 2028
Est. completion
P1P2Cardiac Glycogenosis
ATR 1072 in Participants With PRKAG2 Syndrome
NCT07738107n=37
Jun 2028
Est. completion
Cancer
Patient Descriptors Of Cancer-Related Fatigue: A Mixed Methods Pilot Study Of Cancer Survivors
NCT06634381n=80
Jun 2028
Est. completion
P2IDH1 Mutation
Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
NCT07471841n=25
Jun 2028
Est. completion
P2Female Breast Carcinoma
Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer
NCT02942355n=40

Awaiting Results (6)

Trials past primary completion date but still active — data readout may be imminent.

Nov 2026
NA
A Novel Dialectical Behavior Therapy Brief Group Intervention for Cigarette Smoking by Patients With Cancer: An Open Clinical Trial
NCT07119489
May 2026
NA
Evaluating Microarray Pharmacogenetic Testing in Cancer Patients
NCT06489041
Mar 2026
P2
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
NCT06523621
Oct 2025
NA
Pilot Study of SGRT Alone vs. SGRT With Fiducials for Breath Hold SBRT tx of the Lung
NCT04060927
Apr 2024
Evaluating Learning Curves and Competence in Colorectal Endoscopic Mucosal Resection Among Advanced Endoscopy Trainees
NCT06376006
Jul 2023
P2
Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC
NCT03141359

Recent Press Releases

Atrium Therapeutics to Present Nonclinical Data Showing ATR 1072 Reversed and Improved Features of PRKAG2 Syndrome During HCMS at AHA Scientific Sessions 2026
Nov 2, 2026 · PRNewsWire
Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome
Oct 27, 2026 · PRNewsWire
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Oct 20, 2026 · PRNewsWire
Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive Financing
Oct 20, 2026 · PRNewsWire
Atrium Therapeutics Announces $50 Million Private Placement
Oct 8, 2026 · PRNewsWire
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Sep 21, 2026 · PRNewsWire
Atrium Therapeutics to Participate in Upcoming Investor Conferences
Sep 2, 2026 · PRNewsWire
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 20, 2026 · PRNewsWire
Atrium Therapeutics Reports Second Quarter 2026 Financial Results
Aug 13, 2026 · PRNewsWire
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
Aug 13, 2026 · PRNewsWire

SEC Filings (38)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 2, 20268-KMaterial eventDocumentIndex
Oct 27, 20268-KMaterial eventDocumentIndex
Oct 9, 20268-K/AMaterial eventDocumentIndex
Oct 8, 20268-KMaterial eventDocumentIndex
Aug 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 14, 2026SC 13GPassive 5%+ stakeDocumentIndex
Aug 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 13, 202610-QQuarterly reportDocumentIndex
Aug 13, 20268-KMaterial eventDocumentIndex
Jul 27, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jul 14, 20268-KMaterial eventDocumentIndex
May 15, 2026SC 13GPassive 5%+ stakeDocumentIndex
May 14, 202610-QQuarterly reportDocumentIndex
May 14, 20268-KMaterial eventDocumentIndex
Apr 27, 2026SC 13GPassive 5%+ stakeDocumentIndex
Apr 17, 2026S-8Employee stock planDocumentIndex
Apr 8, 2026SC 13GPassive 5%+ stakeDocumentIndex
Mar 9, 202615-12GDocumentIndex
Feb 27, 20268-KMaterial eventDocumentIndex
Feb 27, 202625-NSEDocumentIndex
Feb 27, 2026POSASRDocumentIndex
Feb 27, 2026POSASRDocumentIndex
Feb 27, 2026POSASRDocumentIndex
Feb 27, 2026S-8 POSEmployee stock planDocumentIndex
Feb 27, 2026S-8 POSEmployee stock planDocumentIndex
Feb 27, 2026S-8 POSEmployee stock planDocumentIndex
Feb 27, 2026S-8 POSEmployee stock planDocumentIndex
Feb 27, 2026S-8 POSEmployee stock planDocumentIndex
Feb 27, 2026S-8 POSEmployee stock planDocumentIndex
Feb 27, 20268-KMaterial eventDocumentIndex
Feb 26, 20268-KMaterial eventDocumentIndex
Feb 26, 20268-KMaterial eventDocumentIndex
Feb 26, 2026S-8Employee stock planDocumentIndex
Feb 26, 2026SEC STAFF ACTIONDocumentIndex
Feb 26, 2026CERTDocumentIndex
Feb 17, 202610-12B/ADocumentIndex
Jan 30, 202610-12B/ADocumentIndex
Dec 10, 202510-12BDocumentIndex